University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "GASTROINTESTINAL"



Treatment trials which apply specifically to your search:


0C-10-4

Trial Leaders:
Anthony El-Khoueiry

A Phase Ia/Ib Clinical Trial of PRI-724 in Patients with Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-10-8

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-2

Trial Leaders:
David Quinn

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients.

Treatment:
Chemotherapy: Systemic

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-12-4

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Multi-Center, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies.

Treatment:
Chemotherapy: Systemic

0C-12-6

Trial Leaders:
Anthony El-Khoueiry

A Phase IB Ascending Multi-Arm, Dose Escalation Study of BMS-906024 Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-4

Trial Leaders:
Heinz Josef Lenz

A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-13-8

Trial Leaders:
Heinz Josef Lenz

A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies

Treatment:
Chemotherapy: Systemic

0C-14-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-14-3

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-5

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Dose Escalation Study of PF-06664178 In Patients with Locally Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
Tanya Dorff

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-11-12

Trial Leaders:
Kevin Kelly

Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination with the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.

Treatment:
Chemotherapy: Systemic

0S-13-4

Trial Leaders:
James Hu

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) vs. Bleomycin, Etoposide and Cisplatin (BEP) for Patients with Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

11S-12-1

Trial Leaders:
James Hu

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung.

Treatment:
Chemotherapy: Systemic

13NHL-12-1

Trial Leaders:
Ann Mohrbacher

A Phase I Study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma.

Treatment:
Immunotherapy

15HD-13-1

Trial Leaders:
Anil Tulpule

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Treatment:
Chemotherapy: Systemic

16M-11-1

Trial Leaders:
Ann Mohrbacher

A Phase II Study of Lenalidomide and Low-Dose Dexamethasone in Combination with Dalteparin in Previously Untreated Multiple Myeloma.

Treatment:
Chemotherapy: Systemic

16M-13-1

Trial Leaders:
Kevin Kelly

A Phase I/IIA Multi-Dose Escalation Study of BT062 in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma.

Treatment:
Chemotherapy: Systemic
Immunotherapy

16M-13-2

Trial Leaders:
Ann Mohrbacher

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Treatment:
Chemotherapy: Systemic

1B-10-3

Trial Leaders:
Julie Lang

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2.

Treatment:
Chemotherapy: Systemic

1B-11-5

Trial Leaders:
Agustin Garcia

A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response.

Treatment:
Other

1B-12-1

Trial Leaders:
Christina M. Dieli-Conwright

Combined Exercise Program for Early Breast Cancer Survivors.

Treatment:
(No treatments specified)

1B-12-10

Trial Leaders:
Agustin Garcia

Phase II Trial of Metronomic Capecitabine and Cyclophosphamide with Lapatinib and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen.

Treatment:
Chemotherapy: Systemic
Immunomodulator

1B-12-3

Trial Leaders:
Agustin Garcia

“PRESENT”: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment.

Treatment:
Vaccine

1B-13-1

Trial Leaders:
Agustin Garcia

A Phase II Study of Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-13-10

Trial Leaders:
Agustin Garcia

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer. (The “METRIC” Study)

Treatment:
Chemotherapy: Systemic

1B-13-11

Trial Leaders:
Agustin Garcia

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician’s Choice In Previously-Treated, HER2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment:
Chemotherapy: Systemic

1B-14-1

Trial Leaders:
Agustin Garcia

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)

Treatment:
Chemotherapy: Systemic

1B-14-2

Trial Leaders:
Agustin Garcia

A Phase II, Open-Label, Multi-Center Study of ANG1005 in HER2+ or Triple Negative Breast Cancer Patients with New or Recurrent Brain Metastases

Treatment:
Chemotherapy: Systemic

1B-14-3

Trial Leaders:
Agustin Garcia

A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-14-4

Trial Leaders:
Agustin Garcia

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Treatment:
Chemotherapy: Systemic

2N-12-5

Trial Leaders:
Barbara Gitlitz

A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination with the MEK Inhibitor Trametinib in Subjects with BRAF V600E Mutation-Positive Metastatic (Stage IV) Non-Small Cell Lung Cancer.

Treatment:
Chemotherapy: Systemic

2N-12-6

Trial Leaders:
Barbara Gitlitz

A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-Small Cell Lung Cancer (NSCLC).

Treatment:
Chemotherapy: Systemic

2N-13-4

Trial Leaders:
Barbara Gitlitz

A Randomized Phase II Trial of Cytotoxic Chemotherapy with or without Epigenetic Priming in Patients with Advanced Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-13-7

Trial Leaders:
Barbara Gitlitz

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

2N-14-3

Trial Leaders:
Eugene Chung

Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-Small Cell Lung Cancer

Treatment:
Radiation: External
Surgery

3C-12-5

Trial Leaders:
Heinz Josef Lenz

A Phase IB/II Multi-Center, Open-Label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients with BRAF Mutant Metastatic Colorectal Cancer.

Treatment:
Chemotherapy: Systemic
Immunotherapy

3C-12-6

Trial Leaders:
Heinz Josef Lenz

Steam (Sequencing Triplet with Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer.

Treatment:
Chemotherapy: Systemic

3C-13-4

Trial Leaders:
Heinz Josef Lenz

An Open-Label, Multi-Center, Randomized Phase 1B/2 Study of Pf-05212384 plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) versus Bevacizumab plus Folfiri In Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic

3C-13-6

Trial Leaders:
Jane Figueiredo

A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers.

Treatment:
(No treatments specified)

3C-14-1

Trial Leaders:
Heinz Josef Lenz

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Treatment:
Chemotherapy: Systemic

3G-13-1

Trial Leaders:
Heinz Josef Lenz

An Open-Labeled, Multi-Center Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma.

Treatment:
Chemotherapy: Systemic

3G-13-2

Trial Leaders:
Heinz Josef Lenz

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with Trastuzumab in Patients with HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Treatment:
Chemotherapy: Systemic

3L-12-3

Trial Leaders:
Anthony El-Khoueiry

A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis.

Treatment:
Immunotherapy

3L-13-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Treatment:
Chemotherapy: Systemic

3P-12-1

Trial Leaders:
Heinz Josef Lenz

Phase IB Multi-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Anti-Neoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ß-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX).

Treatment:
Chemotherapy: Systemic

3R-12-2

Trial Leaders:
Afsaneh Barzi

Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
Immunomodulator

4B-06-1

Trial Leaders:
David Quinn

A Phase I/II Study of E7389 Halichondrin B Analog (NSC #707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency.

Treatment:
Chemotherapy: Systemic

4B-14-1

Trial Leaders:
David Quinn

A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer

Treatment:
Biological Response Modifier

4K-12-2

Trial Leaders:
David Quinn

Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma.

Treatment:
Biological Response Modifier
Immunotherapy

4K-13-1

Trial Leaders:
David Quinn

A Randomized Phase II Study of AMG386 With or Without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
Immunotherapy

4K-13-3

Trial Leaders:
David Quinn

Adjuvant Axitinib Treatment of Renal Cancer: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib vs. Placebo In Subjects At High Risk Of Recurrent RCC

Treatment:
Chemotherapy: Systemic

4P-06-3

Trial Leaders:
Jacek Pinski

A Phase I/II Trial of Adjuvant Post-Prostatectomy 3-D Conformal Radiation Therapy, Hormonal Therapy, and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer.

Treatment:
Chemotherapy: Systemic
Hormone
Radiation: External

4P-09-5

Trial Leaders:
David Quinn

A Randomized Phase II Trial of 177Lu Radiolabeled Monochlonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy.

Treatment:
Immunomodulator

4P-09-9

Trial Leaders:
Jacek Pinski

A Phase I/II Trial of AN-152 [AEZS-108] in Castration- and Taxane-Resistant Prostate Cancer.

Treatment:
Chemotherapy: Systemic

4P-10-8

Trial Leaders:
Tanya Dorff

PREVAIL: A Multi-National Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy.

Treatment:
Chemotherapy: Systemic

4P-12-1

Trial Leaders:
Tanya Dorff

A Randomized Phase II Trial of Dasatinib plus Abiraterone Compared to Abiraterone Alone for Metastatic, Castration-Resistant Prostate Cancer Prior to Chemotherapy.

Treatment:
Chemotherapy: Systemic

4P-12-6

Trial Leaders:
David Quinn

A Randomized Gene Fusion Stratified Phase II Trial of Abiraterone With or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer.

Treatment:
Chemotherapy: Systemic

4P-13-2

Trial Leaders:
E. Todd Schroeder

Exercise and Whey Protein Supplementation as Adjunctive Therapy for Patients with Prostate Cancer Receiving Androgen Deprivation Therapy.

Treatment:
Other

4P-13-5

Trial Leaders:
David Quinn

A Randomized, Open-Label, Phase 2 Study of Sipuleucel-T with Concurrent versus Sequential Administration of Enzalutamide in Men with Metastatic Castrate-Resistant Prostate Cancer

Treatment:
Chemotherapy: Systemic
Immunotherapy

4P-14-1

Trial Leaders:
Mitchell Gross

Phase 2 Trial of Phenelzine in Non-Metastatic Recurrent Prostate Cancer

Treatment:
Chemotherapy: Systemic

5C-11-2

Trial Leaders:
Agustin Garcia

Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer.

Treatment:
Chemotherapy: Systemic

5GYN-13-1

Trial Leaders:
Agustin Garcia

The MILO Study (MEK Inhibitor in Low-Grade Serous Ovarian Cancer): A Multi-National, Randomized, Open-Label Phase III Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

Treatment:
Chemotherapy: Systemic

5GYN-13-2

Trial Leaders:
Agustin Garcia

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Treatment:
Chemotherapy: Systemic

5U-13-1

Trial Leaders:
Agustin Garcia

PhII-129 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer

Treatment:
Chemotherapy: Systemic

5U-14-1

Trial Leaders:
Agustin Garcia

Randomized Controlled Study Comparing AEZS-108 with Doxorubicin As Second Line Therapy For Locally Advanced, Recurrent Or Metastatic Endometrial Cancer

Treatment:
Chemotherapy: Systemic

6G-08-1

Trial Leaders:
Thomas Chen

A Prospective, Multi-Center Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM.

Treatment:
Chemotherapy: Systemic
Other

6G-11-2

Trial Leaders:
Naveed Wagle

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma.

Treatment:
Vaccine

6G-12-2

Trial Leaders:
Naveed Wagle

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma.

Treatment:
Anti-Angiogenesis
Vaccine

7H-13-2

Trial Leaders:
Barbara Gitlitz

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Chemotherapy: Systemic
Immunotherapy

9L-11-8

Trial Leaders:
Ann Mohrbacher

HLA-Mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High-Risk Acute Myeloid Leukemia.

Treatment:
Chemotherapy: Systemic
Other

9L-12-2

Trial Leaders:
Casey O Connell

An Open Label, Randomized (2:1) Phase IIB Study of Dasatinib vs. Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy with 400 mg Imatinib.

Treatment:
Chemotherapy: Systemic

9L-12-5

Trial Leaders:
Akil Merchant

A Phase IB/II Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low-Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.

Treatment:
Chemotherapy: Systemic

9L-12-6

Trial Leaders:
Akil Merchant

An Open-Label, Randomized Phase III Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL).

Treatment:
Chemotherapy: Systemic

9L-13-1

Trial Leaders:
Casey O Connell

Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN)

Treatment:
(No treatments specified)

9L-13-2

Trial Leaders:
Casey O Connell

Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of

Treatment:
(No treatments specified)

9L-13-7

Trial Leaders:
Akil Merchant

A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

Treatment:
Chemotherapy: Systemic

9L-14-1

Trial Leaders:
Kevin Kelly

A multi-center, open-label, phase 1/1b Study of escalating doses of RO5503781 Administered orally as 1) a single Agent, 2) in combination with cytarabine, Or 3) with cytarabine and anthracycline In patients with acute myelogenous Leukemia (AML)

Treatment:
Chemotherapy: Systemic

CTSU-E1411

Trial Leaders:
Anil Tulpule

Intergroup Randomized Phase II Four Arm Study In Patients =/>60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab + Bendamustine Followed By Rituximab Consolidation (RB-R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R); Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR); or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV-LR).

Treatment:
Chemotherapy: Systemic
Immunomodulator
Immunotherapy

CTSU-E2810

Trial Leaders:
David Quinn

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

Treatment:
Anti-Angiogenesis

CTSU/A031201

Trial Leaders:
Amir Goldkorn

Phase III Trial of Enzalutamide (NSC # 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Treatment:
(No treatments specified)

ctsu/CALGB-A011202

Trial Leaders:
Heather R. Macdonald

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

CTSU/CALGB-A021202

Trial Leaders:
Syma Iqbal

Prospective Randomized Phase II Trial Of Pazopanib (NSC # 737754, IND 75648) Versus Placebo In Patients With Progressive Carcinoid Tumors

Treatment:
Chemotherapy: Systemic

CTSU/CALGB/SWOG-C80702

Trial Leaders:
Heinz Josef Lenz

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.

Treatment:
Chemotherapy: Systemic

ctsu/Calgb90601

Trial Leaders:
James Hu

A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

CTSU/E2108

Trial Leaders:
Julie Lang

A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

Treatment:
Chemotherapy: Systemic

CTSU/E2211

Trial Leaders:
Syma Iqbal

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors.

Treatment:
Chemotherapy: Systemic

CTSU/NCCTG-N107C

Trial Leaders:
Eric Chang

A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease.

Treatment:
Radiation: External

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Eugene Chung

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

CTSU/NSABP-B43

Trial Leaders:
Eugene Chung

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In-Situ Resected by Lumpectomy.

Treatment:
Immunotherapy
Radiation: External

CTSU/RTOG-1112

Trial Leaders:
Anthony El-Khoueiry

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Treatment:
Chemotherapy: Systemic
Radiation: External

ctsu/RTOG0848

Trial Leaders:
Syma Iqbal

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Treatment:
Chemotherapy: Systemic
Radiation: External

GOG-0225

Trial Leaders:
Huyen Q. Pham

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?

Treatment:
(No treatments specified)

GOG-9929

Trial Leaders:
Huyen Q. Pham

A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA with Positive Lymph Nodes.

Treatment:
Chemotherapy: Systemic
Immunotherapy
Radiation: External

NC-HEM-14-1

Trial Leaders:
Ilene Weitz

Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.

Treatment:
Other

RTOG-0534

Trial Leaders:
Leslie Ballas

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy.

Treatment:
Hormone
Radiation: External

RTOG-0815

Trial Leaders:
Leslie Ballas

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.

Treatment:
Hormone
Radiation: External

RTOG-0920

Trial Leaders:
Eugene Chung

A Phase III Study of Post-Operative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer.

Treatment:
Immunotherapy
Radiation: External

RTOG-1008

Trial Leaders:
Richard Jennelle

A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors.

Treatment:
Chemotherapy: Systemic
Radiation: External

RTOG-1010

Trial Leaders:
Heinz Josef Lenz

A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma.

Treatment:
Chemotherapy: Systemic
Immunomodulator
Radiation: External
Surgery

RTOG-1203

Trial Leaders:
Suisui Song

A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)

Treatment:
Radiation: External

SWOG-S0820

Trial Leaders:
Syma Iqbal

A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

Treatment:
Other

SWOG-S0905

Trial Leaders:
Barbara Gitlitz

A Phase I/Randomized Phase II Study of Cediranib (NSC #732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma.

Treatment:
Anti-Angiogenesis

SWOG-S0931

Trial Leaders:
Tanya Dorff

EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.

Treatment:
Anti-Angiogenesis

SWOG-S1007

Trial Leaders:
Agustin Garcia

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1011

Trial Leaders:
Siamak Daneshmand

A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.

Treatment:
Surgery

SWOG-S1200

Trial Leaders:
Agustin Garcia

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer.

Treatment:
Other

SWOG-S1201

Trial Leaders:
Syma Iqbal

A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer.

Treatment:
Chemotherapy: Systemic

SWOG-S1206

Trial Leaders:
Barbara Gitlitz

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Treatment:
(No treatments specified)

SWOG-S1207

Trial Leaders:
Agustin Garcia

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1211

Trial Leaders:
Kevin Kelly

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High-Risk Multiple Myeloma (HRMM).

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
Immunomodulator
Immunotherapy

SWOG-S1216

Trial Leaders:
David Quinn

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1304

Trial Leaders:
Kevin Kelly

A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease.

Treatment:
Chemotherapy: Systemic

SWOG-S1310

Trial Leaders:
Anthony El-Khoueiry

Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer

Treatment:
Chemotherapy: Systemic

SWOG-S1313

Trial Leaders:
Syma Iqbal

A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.

Treatment:
Chemotherapy: Systemic

SWOG-S1314

Trial Leaders:
Siamak Daneshmand

A Randomized Phase II Study of Co-Expression Extrapolation (Coxen) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Treatment:
Chemotherapy: Systemic

SWOG-S1400

Trial Leaders:
Jorge Nieva

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

Phase I trials for all solid tumors:


0C-10-4

Trial Leaders:
Anthony El-Khoueiry

A Phase Ia/Ib Clinical Trial of PRI-724 in Patients with Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-10-8

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-906024 in Subjects with Advanced Solid Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-1

Trial Leaders:
Anthony El-Khoueiry

A Phase I Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Crizotinib in Advanced Cancer Patients.

Treatment:
Chemotherapy: Systemic

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-12-6

Trial Leaders:
Anthony El-Khoueiry

A Phase IB Ascending Multi-Arm, Dose Escalation Study of BMS-906024 Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Tumors.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-14-1

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-3

Trial Leaders:
Anthony El-Khoueiry

Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-14-5

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Dose Escalation Study of PF-06664178 In Patients with Locally Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-00-15

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer.


0S-00-16

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer.


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-06-8

Trial Leaders:
Akil Merchant

Ethnic Differences in Hematologic Malignancies


0S-08-15

Trial Leaders:
Charite Ricker

Cancer Genetics Family Registry - Molecular Genetics Studies of Cancer Patients and Their Relatives.


0S-08-5

Trial Leaders:
Darcy Spicer

Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project.


0S-10-1

Trial Leaders:
Florence Wong

A Survey of Complementary and Alternative Medicine (CAM) Use and Interest to Participate in CAM Research Studies in a Comprehensive Cancer Center.


0S-11-3

Trial Leaders:
Charite Ricker

Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-11-9

Trial Leaders:
Michael Wong

Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-12-6

Trial Leaders:
Heinz Josef Lenz

Assessing the Patient Experience in Cancer Care: An Observational Communication Study.


0S-13-1

Trial Leaders:
Gregory Idos

USC Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing


0S-14-1

Trial Leaders:
Ilya Lekht

The DFINE STAR™ Tumor Ablation Prospective Clinical Series


0S-99-10

Trial Leaders:
Heinz Josef Lenz

Blood Collection in Patients with GI Cancer.


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-4

Trial Leaders:
Marisa Perdomo

Screening for Musculoskeletal Impairments and Quality of Life in Individuals Post-Treatment for Breast Cancer.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-12-9

Trial Leaders:
Agustin Garcia

An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer.


1B-13-8

Trial Leaders:
Linda Hovanessian

Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer.


2L-10-1

Trial Leaders:
Barbara Gitlitz

Addario Lung Cancer Medical Institute (ALCMI) Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.


2L-14-1

Trial Leaders:
Barbara Gitlitz

Genomics of Young Lung Cancer Study


2N-12-7

Trial Leaders:
Daniel Oh

DNA Methylation Markers for Detecting Cancer Cells in Malignant Pleural Effusion.


2O-13-1

Trial Leaders:
Barbara Gitlitz

Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer


3C-13-2

Trial Leaders:
Afsaneh Barzi

A Pilot Study of Monitoring Metastatic Colorectal Cancers with Liquid Biopsies.


3G-07-2

Trial Leaders:
Heinz Josef Lenz

Early Onset and Familial Gastric Cancer Registry.


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


3G-07-4

Trial Leaders:
Heinz Josef Lenz

Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers.


4B-13-1

Trial Leaders:
Siamak Daneshmand

4B-13-1 Cysview® Blue Light Cystoscopy Registry


4B-13-4

Trial Leaders:
Siamak Daneshmand

Evaluation of the UroVysion™ Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade Ta-T1 and CIS Urothelial Carcinoma of the Bladder


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


4K-13-2

Trial Leaders:
Vinay Duddalwar

CT Metrology: Quantitative Imaging Metrics with Advanced Visualization Tools for Cancer Imaging


4P-01-2

Trial Leaders:
Eila Skinner

Prostate Cancer Prostatectomy Data and Specimen Collection Project.


4P-11-4

Trial Leaders:
Mitchell Gross

Multi-Dimensional Assessment of Circulating Tumor Cells in Patients Treated For Metastatic Prostate Cancer.


4P-12-3

Trial Leaders:
Alan Epstein

MDSC Clinical Assay for Cancer Detection and Monitoring in Prostate Cancer.


5GYN-10-3

Trial Leaders:
Lynda Roman

Banking Tissues from Normal and Disease-Related Gynecologic Surgeries.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


9L-10-3

Trial Leaders:
Preet Chaudhary

Comprehensive Hematology Tissue Repository (BANK).


ACRIN 6685

Trial Leaders:
John L. Go

A Multi-Center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients.


ACRIN 6690

Trial Leaders:
Suzanne Palmer

A Prospective, Multi-Center Comparison of Multi-Phase Contrast-Enhanced CT and Multi-Phase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation.


ACRIN 6701

Trial Leaders:
Suzanne Palmer

Repeatability Assessment of Quantitative DCE-MRI and DWI: A Multicenter Study of Functional Imaging Standardization in the Prostate


CTSU/A01104/ACRIN6694

Trial Leaders:
Pulin A. Sheth

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer


NC-HEM-06-5

Trial Leaders:
Anil Tulpule

Retrospective Clinipathologic Analysis of HIV-Associated Hodgkin’s Disease.


NC-HEM-12-1

Trial Leaders:
Anil Tulpule

Inhibition of proteasomal degradation of Nrf2 to augment antioxidant responses in sickle cell anemia


SWOG-S1013

Trial Leaders:
Heinz Josef Lenz

A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities.